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A B S T R A C T
Diabetic foot ulcers (DFU) are notoriously slow to heal and even in cases where primary healing is
achieved ulcers frequently recur. An optimal treatment for DFU would be one that supports both rapid
and long-term healing. Our purpose is to evaluate recurrence rates of DFU healed with use of dehydrated
human amnion/chorion membrane (dHACM). Twenty-two patients with chronic DFU that healed with
the use of dHACM were eligible for inclusion. All eligible patients had completed a single-center
randomized clinical trial comparing rates of primary healing over a 12 week period with dHACM versus a
standard regimen of care [20] (Zelen et al., 2013). Follow-up examinations were scheduled for 9–12
months after primary healing with dHACM. Subsequent evaluation of clinical records was made with IRB
approval and patient consent. Eighteen of 22 eligible patients (81.8%) returned for follow-up
examination. Mean wound size prior to treatment with dHACM was 3.1  3.8 cm2, median 1.7 cm2
(0.7, 13.5). Mean time to wound closure after dHACM initiation was 3.1  2.8 weeks (median 2.0 weeks,
range 1.0–9.0 weeks). At the 9–12 month follow-up visit 17 of 18 (94.4%) wounds treated with dHACM
remained fully healed. These ﬁndings support the effectiveness of dHACM for treatment of DFU.
  2013  Elsevier  GmbH.  
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Identiﬁcation and implementation of the ideal treatment
regimen for patients with diabetic foot ulcers is an increasingly
common issue faced by clinicians worldwide. Due to factors such as
peripheral vascular disease, neuropathy, and poor blood glucose
control, diabetic ulcers are notoriously slow to heal. Underscoring
the need for rapid healing, Lavery et al. reported that ulcer duration
of greater than 30 days was independently associated with a 4.7-fold
increase in infection, and that an infected foot ulcer increased the
risk of hospitalization by nearly 56 times and risk for amputation by
nearly 155 times [1]. Therapies that promote rapid and complete
healing, thus reducing the risk for infection and amputation, can
substantially improve quality of life while decreasing ﬁnancial
burdens to the individual and society overall [2].
Even in cases where primary healing occurs, studies have
shown that despite ongoing intensive foot care, diabetic ulcersAbbreviation: dHACM, dehydrated human amniotic/chorionic membrane.
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Open access under CC BY-NC-ND license.frequently recur – either in the same location or elsewhere on the
foot [3,4]. Overall recurrence rates of 35–60% over 3 years,
increasing to 70% over 5 years have been reported [5]. In one
study of patients with recurrent diabetic foot ulcers, 34.4% of
wounds recurred in the exact location as a previous ulcer, and
almost 60% of recurrent ulcers appeared within 12 months of
primary healing [6]. Indeed, it has been suggested that patients
with a healed ulcer should not be referred to as cured, but rather as
being in remission [7].
Natural human amniotic membrane has been used as a
wound covering for over 100 years [8]. However, there are often
issues relative to obtaining, preparing, and storing the tissue for
use in clinical practice, as well as concern regarding the
potential for infectious disease transmission. Recently, a system
has been identiﬁed to gently process, sterilize and dry placental
tissue obtained from screened and tested pregnant women
scheduled to undergo Cesarean delivery. This proprietary
process is used to create a dehydrated human amnion/chorion
membrane (dHACM) allograft that can be stored at ambient
temperature for up to 5 years (EpiFix1 MiMedx Group, Inc.,
Marietta, GA) [9].
Comprising the innermost layer of the placenta, the amniotic
membrane consists of a thin epithelial layer, a thick basement
membrane and an avascular stroma [10]. These materials provide
Table 1
Clinical characteristics.
Variable N = 18
Male gender (n/%) 5/27.8
Age (year) 58.8  12.8
58.5 (31, 80)
BMI (kg/m2) 32.7  6.7
31.4 (23.1, 51.6)
Obese (>29.9 kg/m2) (n/%) 10/55.5
Smoker (n/%) 3/16.7
Caucasian race (n/%) 15/83.3
Wound size (cm2) at 1st application of dHACM 3.1  3.8
1.7 (0.7, 13.5)
Wound duration (weeks) at 1st application of dHACM 19.4  13.6
14.0 (6.0, 54.0)
Ulcer location (n/%)
Forefoot or digital 9/50
Heel or midfoot 9/50
Time to healing with dHACM (weeks) 3.1  2.8
2.0 (1.0, 9.0)
Data presented as mean  SD, median (min, max), or number (percent) as indicated.
BMI = body-mass-index.
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cells and a large number of important regenerative molecules
[11,12]. Collagens type IV, V and VII provide an important substrate
which is not only important for the structural integrity of the
membrane but also facilitates wound healing and cellular
ingrowth. Natural amniotic membrane has been shown to be
antimicrobial, and can reduce pain, inﬂammation and scar tissue
formation at the site of application; the membrane also contains
essential growth factors and cytokines that may enhance the
healing process [12–16].
Several case studies and clinical reports on the use of dHACM in
various types of wounds are available [17–19]. In a recent
randomized clinical trial of patients with chronic diabetic foot
ulcers treated with biweekly application of dHACM versus a
standard regimen of wound care, primary healing occurred in 92%
of ulcers (12/13) treated with dHACM and only 8% of ulcers (1/12)
receiving a standard protocol of wound care (moist wound
therapy) in the 12 week study period [20]. Those patients that
failed to heal in the randomized trial (n = 11) were subsequently
treated with dHACM resulting in primary healing of 91% of diabetic
ulcers (10/11) [21]. The purpose of the current investigation is to
examine rates of ulcer recurrence within one year of treatment
with dHACM.
2. Materials and methods
We conducted a follow-up study of patients previously enrolled
in an IRB approved randomized clinical trial [20] comparing rates
of primary healing with dHACM versus a standard protocol of
wound care (moist wound therapy) over a 12 week period.
Enrolled in the original study [20] were patients with type 1 or type
2 diabetes having a non-healing (minimum of 6 weeks duration)
diabetic ulcer anywhere on the foot. Study inclusion/exclusion
criteria and study procedures have been described in the previous
publication [20]. Complete healing was deﬁned as total epithelial-
ization of the open area of the wound. Failure to heal was deﬁned
as less than 50% decrease in wound size after 6 weeks of study
participation or not having completely healed within 12 weeks.
At completion of the clinical trial [20] those patients random-
ized to the standard care group who had not healed (n = 11) were
then treated with biweekly application of dHACM [21].
Included in the present study are those patients from the initial
randomized trial that were randomized to the dHACM treatment
group and healed within 12 weeks and those that were
randomized to standard treatment with moist wound care that
subsequently received dHACM and healed after initial study
completion. The study was conducted in a single center in
Southwest Virginia under the direction of a senior clinician
(CMZ) with expertise in diabetic foot care. Patients read and signed
an IRB approved informed consent form prior to enrollment in the
initial study and provided additional IRB approved consent for the
current review of subsequent data and outcomes.
2.1. dHACM therapy
Prior to application of dHACM to the wound all necrotic tissue
was removed using surgical debridement. The dHACM allograft
was then covered with a non-adherent dressing (Adaptic1),
followed by a moisture-retentive dressing (hydrogel) and a
compression dressing. All wounds were ofﬂoaded using a
removable cast walker (Active Ofﬂoading Walker; Darco of
Huntington; West Virginia). Weekly clinic visits were required
for wound assessment and dressing changes. All patients were
seen by the investigator weekly for up to 12 weeks or until
complete healing, whichever occurred ﬁrst. During each weekly
visit, ulcer cleansing with a sterile normal saline solution (rinsing,swabbing or irrigating), ulcer measurement with a graded
centimeter ruler (length, width and depth) and a dressing change
was conducted. When applicable, measurements were done after
debridement. The wound area was calculated by multiplying the
width and length measurements. An additional dHACM allograft
was applied at week 2, week 4, week 6, week 8, and week 10 if the
ulcer had not completely epithelialized. After healing was
achieved patients were instructed on an intensive diabetic foot
care routine and advised to wear diabetic shoes with insoles for
ambulation. Strict blood glucose control was encouraged and
monitored by each patient’s private physician. Follow-up via
clinic visits were encouraged and performed on a regular basis in
majority of the patient population, in most instances every three
to four months.
2.2. Study outcome
In this current study we sought to determine rates of ulcer
recurrence within one year of primary healing with dHACM.
3. Results
Twenty-ﬁve patients were enrolled in the initial randomized
trial. Of those 25, 13 were randomized to receive dHACM and 12 of
13 (92.3%) healed at a mean of 2.5  1.9 weeks [20]. Of the 12
patients randomized to receive the standard regimen of care, one
healed, and 11 exited the randomized study without healing and
subsequently received dHACM [21]. Of these 11 patients, 10 (91%)
healed completely within 9 weeks of starting treatment with dHACM
(mean 4.2  3.1 weeks) [21]. Twenty-two of 25 patients (88%)
ultimately had complete healing of their diabetic foot ulcer after
treatment with dHACM and were eligible for inclusion in the follow-
up study. Four were lost to follow-up. Clinical characteristics of the 18
patients with follow-up data are presented in Table 1. Overall, at time
of ﬁrst dHACM allograft placement the foot ulcers had been present
for a mean of 19.4  13.6 weeks, median 14.0 weeks, range 6.0–54.0
weeks. Mean wound size at initiation of dHACM was 3.1  3.8 cm2.
Eighteen patients returned to the clinic for follow up
examination 9–12 months after healing (mean time from healing
to follow-up was 11.2 months). At long term follow up 17 of the 18
ulcers remained healed (94.4%). The wound that reopened did so
despite off loading with appropriate diabetic insoles and follow up
podiatric care. Photos of wounds at time of initial application of
dHACM, primary healing, and at follow-up are presented in Fig. 1.
Fig. 1. Images of wounds at 1st dHACM application, when healed, and at long term follow-up visit.
C.M. Zelen et al. / Wound Medicine 4 (2014) 1–4 34. Discussion
In the present study of 18 patients with chronic diabetic foot
ulcers that healed within 12 weeks after treatment with dHACM,
all but one treated ulcer (94.4%) remained healed almost one year
later. These results support the results of the original clinical trial[20] and the second crossover study [21] showing that dHACM is
an effective treatment for closure of diabetic foot ulcers.
The pathogenesis of foot ulcers is often complex and their
management is difﬁcult. Knowledge of new techniques, technolo-
gy and products can allow the clinician to excel in their effort to
provide optimal care and promote positive outcomes for these
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gineered skin substitutes and wound care technologies such as the
topical gel becaplermin (Regranex1, Systagenix Wound Manage-
ment) and living skin equivalents Apligraf1 (Organogenesis) and
Dermagraft1 (Shire Regenerative Medicine) have been shown to
accelerate the healing process in many patients, yet there is no
perfect treatment for all patients in all situations [22].
Treatments which can accelerate the healing process, thus
reducing the risk for infection, are highly desirable in the
management of diabetic ulcers, although it is also important to
assess if healing is maintained over a longer period of time.
Apelqvist et al. [5] reported an ulcer recurrence rate of 34%, 61%
and 70% at 1, 3 and 5 years after primary healing respectively. In
another study of patients with recurrent diabetic foot ulcers, it was
reported that 34.4% of ulcers recurred in the location of a previous
ulcer, and recurrence occurred within 12 months of primary
healing in almost 60% of patients [6]. In the present study of
patients treated with dHACM only 1 of 18 patients (5.5%)
experienced a recurrent diabetic foot ulcer.
A proprietary process of advanced tissue stabilization and
preservation has allowed for widespread use of human amniotic
membrane in the form of a dHACM allograft [9]. The dehydrated
allograft is operationally efﬁcient as it can be transported and
stored at ambient temperature up to 5 years, minimizing the need
for complex policies for receiving and storing certain graft
materials that may require subzero refrigeration, or may have a
short storage life that often leads to wasted product. Handling
characteristics of the dHACM material minimizes time for
application which improves clinically efﬁciency. The dHACM is
provided in a number of different sizes, minimizing waste when
used on ulcers of various sizes and at various stages in the healing
process.
Limitations of the current study are inherent to those of a
retrospective study design and small sample size. Four patients
were lost to follow-up and we are unaware of the status of their
wound. Larger studies are needed to conﬁrm our ﬁndings.
5. Conclusion
Prior studies have shown that dHACM can promote rapid
healing of diabetic ulcers with a 97.1  7.0% reduction in wound size
within 4 weeks of ﬁrst allograft application [20]. Long term follow-up
of wounds treated with dHACM showed that 94.4% of these wounds
remained closed. These results illustrate that dHACM promotes both
rapid and sustained healing. dHACM appears to be a viable treatment
option for the management of recalcitrant diabetic foot ulcers.
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